Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit

Posted: December 2, 2022 at 12:43 am

Highlighting TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor to treat chronic myeloid leukemia Highlighting TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor to treat chronic myeloid leukemia

See original here:
Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit

Related Posts